Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Public Health Professionals
- Remove People with Substance Use or Abuse Problems as Audience
- Remove Substance Abuse
- Remove Co-Occurring Disorders
- Remove English
- Remove Practitioner/Professional
- Remove Buprenorphine
- Remove Tobacco
- Remove Methadone
- Remove Oxycodone
- Remove Hallucinogens
Main page content
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health
Published: September 2017
This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.